Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer
This study is testing a new way to help patients with a specific type of breast cancer handle their treatment better. The goal is to see if adding a blood sugar medication can lower the common side effect of high blood sugar caused by standard cancer treatments.
This trial is for adults who have breast cancer that has spread, is HER2-negative, and has tested positive for hormone receptors. Participants must be post-menopausal and meet specific health criteria, such as not having Type 1 diabetes.
Participants will take a daily tablet called dapagliflozin alongside their regular cancer medications. You will be monitored closely by the medical team to see how your body responds to this combination.
The study is located in Kansas City, Missouri. Its current status is listed as unknown, so you should contact the research team to see if they are currently enrolling new patients.
- 1Focuses on reducing high blood sugar, a common side effect of breast cancer therapy.
- 2Combines a proven blood sugar medication with standard cancer-fighting drugs.
- 3Specifically designed for patients whose breast cancer is hormone-receptor positive and HER2-negative.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.